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Abstract
Airway smooth muscle (ASM) plays a major role in acute airway narrowing and 
reducing ASM thickness is expected to attenuate airway hyper-responsiveness and 
disease burden. There are two therapeutic approaches to reduce ASM thickness: (a) 
a direct approach, targeting specific airways, best exemplified by bronchial thermo-
plasty (BT), which delivers radiofrequency energy to the airway via bronchoscope; 
and (b) a pharmacological approach, targeting airways more broadly. An example of 
the less well-established pharmacological approach is the calcium-channel blocker 
gallopamil which in a clinical trial effectively reduced ASM thickness; other agents 
may act similarly. In view of established anti-proliferative properties of the mac-
rolide antibiotic azithromycin, we examined its effects in naive mice and report a 
reduction in ASM thickness of 29% (p < .01). We further considered the potential 
functional implications of this finding, if it were to extend to humans, by way of a 
mathematical model of lung function in asthmatic patients which has previously been 
used to understand the mechanistic action of BT. Predictions show that pharmaco-
logical reduction of ASM in all airways of this magnitude would reduce ventilation 
heterogeneity in asthma, and produce a therapeutic benefit similar to BT. Moreover 
there are differences in the expected response depending on disease severity, with 
the pharmacological approach exceeding the benefits provided by BT in more severe 
disease. Findings provide further proof of concept that pharmacological targeting of 
ASM thickness will be beneficial and may be facilitated by azithromycin, revealing 
a new mode of action of an existing agent in respiratory medicine.
K E Y W O R D S
airway hyper-responsiveness, asthma
2 of 9 |   DONOVAN et Al.
1 |  INTRODUCTION
Contraction of airway smooth muscle (ASM) drives acute 
airway narrowing in asthma (King, Pare, and Seow 1999). 
As such, reducing the thickness of the ASM layer is a prom-
ising therapy which is yet to be fully exploited. Two distinct 
modalities to reducing ASM thickness are the pharmacolog-
ical approach, such as the calcium channel blocker gallopa-
mil, which in a clinical trial appeared to reduce ASM mass 
(Girodet et  al.,  2015), or more local approaches like bron-
chial thermoplasty (BT), in which specific (large) airways are 
directly targeted using radiofrequency energy delivered via 
bronchoscope (Castro et al., 2010; Cox, Miller, McWilliams, 
Fitzgerald, & Lam,  2006; Cox et  al.,  2007; Pavord 
et al., 2007). There are notable differences between these ap-
proaches. While the degree of ASM reduction achieved by 
gallopamil was less than BT (gallopamil 20% compared with 
as much as 75% for BT), oral administration allows therapeu-
tic processes to take place throughout the bronchial tree. In 
comparison, BT is largely confined to a local area of treat-
ment and this confinement has generated controversy regard-
ing the mechanism of action of BT (Donovan, Elliot, Green, 
James, and Noble 2018).
In this study, we address several pertinent questions. 
Firstly, we trialled the capacity of another clinically relevant 
pharmacological agent, the macrolide antibiotic azithromy-
cin, to reduce ASM mass. Azithromycin was chosen due to 
its anti-proliferative properties, demonstrated in ASM cul-
tures in vitro (Stamatiou et al., 2009), and its role in reduc-
ing asthma exacerbations (Hiles, McDonald, Guilhermino, 
Brusselle, & Gibson, 2019). However, the exact mechanism 
of action has been the subject of much research and remains 
unclear (Parnham et al., 2014). We here show that in naive 
mice, azithromycin reduces ASM thickness, and by a similar 
magnitude to gallopamil (Girodet et  al.,  2015). These data 
help to clarify azithromycin's mechanism of action in asthma: 
that the ASM reduction occurs in naïve mice supports an in-
flammation-independent pathway. It also allows us to add 
azithromycin to the existing work on gallopamil, providing 
further evidence that pharmacological ablation of the ASM 
is a viable approach.
Following on from this finding, we used an established 
mathematical model (Donovan,  2016, 2017; Donovan 
et al., 2018) to consider the effects of potential pharmacolog-
ical reduction of ASM in asthma. That is, if the finding that 
azithromycin reduces ASM mass in naïve mice does extend 
to asthma in humans, what would the expected consequences 
of this be? To this end we examined, by way of the model, 
the relative efficacy of a treatment which globally reduces 
ASM (pharmacological approach), but by a lesser degree, 
as opposed to one with a larger effect on ASM but confined 
to a smaller number of airways (i.e., BT). Such modeling 
has been successful in helping to understand the underlying 
mechanism of action of BT by considering not just the treat-
ment effects on individual airways, but also the ways in which 
the alteration of one airway can affect its neighbors, both via 
flow coupling and airway-parenchymal interdependence 
(Donovan, Elliot, Boser, et al., 2019; Donovan et al., 2018; 
Donovan, Elliot, Green, James, & Noble,  2019; Langton, 
Noble, Thien, & Donovan, 2019). In this way we are able to 
compare the potential benefits of pharmacological therapies, 
which reduce ASM throughout the bronchial tree, with local-
ized therapies, such as BT, in terms of their relative efficacy 
and the specific characteristics of the treatment response.
Overall, the present study combines data from an azithro-
mycin mouse model, demonstrating ASM reduction in vivo, 
with a theoretical approach, using the mathematical model 
to project the consequences of similar reductions in patients 
with asthma. Results indicate that azithromycin does reduce 
ASM thickness and may be at least as effective as BT.
2 |  METHODS
2.1 | Azithromycin mouse model
Adult (9-week-old) male BALB/c mice were obtained from 
the Animal Resources Centre and housed in a pathogen-
free environment at the Telethon Kids Institute. Mice were 
weighed daily, maintained under a 12-hr light/dark cycle 
and given access to food and water ad libitum. The study 
maintained strict compliance to the National Health and 
Medical Research Council's Australian code for the care and 
use of animals for scientific purposes (8th edition, 2013). 
All protocols were approved by the Telethon Kids Institute 
Animal Ethics Committee (Application #339) and The 
University of Western Australia Animal Ethics Committee 
(RA/3/100/1576).
Mice were randomized to receive s.c injection of azith-
romycin or saline (control) for 11 consecutive days (day 0 
to day 10). The dose of azithromycin (50 mg/kg) was based 
on the findings of Beigelman et al. (2009). On day 11, mice 
were euthanized by a two-step process. Following sedation 
with methoxyflurane (Medical Developments International 
Ltd, Springvale, Australia), euthanasia was achieved by bar-
biturate overdose (sodium pentobarbitone, 160 mg/kg by i.p 
injection).
2.2 | Airway morphometry and histology
Bronchoalveolar lavage fluid was initially collected for a 
separate study; lungs were subsequently fixed by intra-tra-
cheal instillation of 4% formaldehyde at a transrespiratory 
pressure of 10 cmH2O (Hsia et al., 2010). The left lobe was 
embedded in paraffin with the proximal end facing down. 
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Two sections from the central bronchus were stained using 
hematoxylin & eosin (Wang et al., 2018). The first section 
was acquired just below the transition from extra- to intra-
parenchymal bronchus (middle region in (Sato, Bartolak-
Suki, Parameswaran, Hamakawa, & Suki,  2015)), and the 
second section marginally deeper into the lung (toward the 
lower region in (Sato et al., 2015)). These regions are here-
after referred to as “Proximal” and “Distal,” respectively. 
The cross-sectional area of ASM layer and internal perimeter 
of the basement membrane (Pbm) were measured using the 
Stereo Investigator software (version 10, MBF Bioscience, 
Vermont, USA). The square roots of areas were then cor-
rected by the Pbm, the standard index of airway size (James, 
Hogg, Dunn, & Pare, 1988). Measurements were performed 
by a blinded observer (KCWW).
Analyses were conducted using two-way ANOVA with 
treatment (saline vs. azithromycin) and location (proximal vs. 
distal) as repeat measures factors (SigmaPlot version 13.0, 
Systat Software Inc).
2.3 | Mathematical model
To consider the potential functional consequences of such a 
reduction of ASM in humans, we adapted a previously de-
veloped mathematical model of BT (Donovan et al., 2018) to 
the context of global reduction of ASM by pharmacological 
means. In brief, the model approach is as follows: the airway 
tree structure is generated using a statistical model fit to exten-
sive structural airway data. This dataset consists of 1,515 indi-
vidual airways from n = 57 donors, and further broken down 
into non-fatal asthma (NFA, n = 32) and fatal asthma (NA, 
n = 25). Subject characteristics are given in Table 1. Formalin 
fixed lung sections from whole left lungs were acquired from 
the Prairie Provinces Fatal Asthma Study (Tough, Green, 
Paul, Wigle, & Butt, 1996) and analyzed as described previ-
ously (Donovan et al., 2018). The measurements of these air-
ways, in terms of Pbm, wall area, ASM area, and anatomical 
level, are used to inform a statistical model of airway structure 
at each airway order (Horsfield, 1990). In this way, simulated 
lung structures of different disease severity can be generated 
by Monte Carlo simulation (Mooney, 1997).
Within these structures, we calculated the functional flow 
patterns using the model developed in (Donovan, 2016, 2017) 
(based on (Anafi & Wilson, 2001; Leary, Winkler, Braune, & 
Maksym, 2014; Venegas et al., 2005)), and subsequently cal-
culated the impedance (including resistance) using a post-hoc 
approach (Lutchen & Gillis, 1997; Thorpe & Bates, 1997). 
In particular, we use the resistance at 5 hz, which is known 
to correlate with other well-known measures such as FEV1 
(Akamatsu et al., 2017; Vink, Arets, van der Laag, & van der 
Ent, 2003). This is done first in the pre-treatment control for 
both NFA and FA. The underlying airway structure is then 
altered according to the treatment protocol; either a 75% re-
duction in ASM mass in the BT-treated airways only, as per 
(Donovan et al., 2018), or a uniform reduction in the ASM 
in all airways. See Figure 1 for a schematic illustration of the 
imposed reductions in ASM for each treatment in the model. 
In the case of pharmacological global treatment, we allowed a 
variable level of reduction to account for potential variations 
in pharmacological effectiveness, assuming either 10%, 20%, 
or 30% reduction in ASM mass in all airways. In all cases, 20 
independent simulations were performed, at varying doses of 
contractile agonist, and we assessed the treatment response of 
that simulated cohort.
Ventilation heterogeneity is characterized using the spa-
tial heterogeneity index (SHI), introduced in (Donovan 
et  al.,  2018). This assessed the heterogeneity of the flow 
Nonfatal 
asthma 
(n = 32)
Fatal asthma 
(n = 25)
Age, years, mean ± SD 35 ± 11 33 ± 14
Gender, male/female 16/16 15/10
Inhaled/oral corticosteroid use, number (%)a 9 (53) 12 (92)† 
Ever smoked, number (%)a 11 (52) 9 (64)
Perimeter of the basement membrane, mm, 
mean ± SD (range)
11.3 ± 1.6 
(1.7–30.8)
11.8 ± 1.6 (1.8–32.5)
Body mass index, mean ± SD (range)a 32 ± 8 (16–45) 26 ± 6 (15–41)*
Age at onset of asthma, years, median (IQR)a 17 (10–26) 9 (3–39)
Duration of asthma, years, median (IQR)a 17 (9–21) 17 (7–22)
Asthma severity, “Severe”, number (%)a 8 (38) 9 (64)
aIncomplete data set. 
*p < .05 versus Nonfatal asthma. 
†p = .04 
T A B L E  1  Subject characteristics from 
(Donovan et al., 2018; Tough et al., 1996)
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using an equally weighted combination of the coefficient of 
variation and the spatial correlation, the latter using Moran's 
I statistic. It attempts to capture both the overall heterogeneity 
of the flow, but also the extent to which this heterogeneity is 
spatially structured (e.g., clustered ventilation defects).
3 |  RESULTS
Mice treated with azithromycin (50  mg/kg for 11  days) 
had reduced ASM compared with control (saline) mice; 
see Figure 2. This effect was present at both proximal and 
distal locations. Testing by repeated measures two-way 
ANOVA revealed a significant effect of azithromycin 
(p  =  .007) with no effect of location (p  =  .670) and no 
interaction (p = .834). The average ASM reduction across 
both locations was 29%.
To assess the effects of such a reduction in asthma, 
simulations of the mathematical model were performed 
assuming different levels of global ASM reduction as 
a result of theoretical pharmacological treatment: 10%, 
20%, or 30% reductions. These were compared with both 
untreated simulations, with no structural changes, and 
simulated BT, with a 75% ASM reduction in the BT-
treated airways only. A sample simulation set is shown in 
Figure 3, with the left-hand panel (a) being untreated, the 
center panel (b) showing the effects of a 30% global re-
duction in ASM, and the right-hand panel (c) showing the 
effects of simulated BT. In both cases, the flow patterns 
have clearly been altered by treatment, and in different 
ways.
Aggregating statistics over the entire simulated cohort, 
for both NFA and FA, and for varying doses of contrac-
tile agonist (e.g., methacholine), yields the dose-response 
curves shown in Figure  4. The left-hand panel is for FA, 
while the right-hand panel is for NFA. In both cases, the 
expected pattern of progressive decreases in resistance 
with further reduction in ASM is apparent. What is also 
apparent is the characteristic lack of response at baseline, 
compared with the clear separation between untreated and 
treated curves as agonist is increased, previously seen in BT 
(Donovan et  al.,  2018). The simulated BT dose-response 
curves are also overlaid (in red) for easy comparison. Note 
the difference in relative response between FA and NFA; in 
the former case, BT is approximately equivalent to a 20% 
reduction in ASM, while in the latter, BT is almost exactly 
equivalent to a 30% reduction in ASM. This difference will 
be considered further in the discussion. The out-of-phase 
component of the impedance (elastance or reactance) dis-
plays qualitatively similar results (data not shown), and an 
estimate of the aggregate of small airway resistance shows 
an approximately 10% shift in favor of the global ASM re-
duction relative to BT.
The changes to the ventilation heterogeneity can be 
more directly quantified using the spatial heterogeneity 
index (SHI), which is constructed so as to reflect not just 
the overall heterogeneity of the flow, but also the extent 
to which it is spatially structured (see methods). The SHIs 
for the simulated cohort are shown in Figure 5, using the 
same presentation style as Figure 4. The same basic con-
clusion is apparent: in FA, BT is approximately equivalent 
to a 20% global reduction in ASM, albeit with a sensitivity 
shift, while in NFA the equivalence is closer to 30% global 
reduction.
FIGURE 1 Schematic of low level global ASM reduction 
(pharmacological; blue) compared with more substantial local ASM 
reduction (BT; red). Perimeter of epithelial basement membrane is used 
as an index of airway size. Elliptical visual aids indicate the airways 
before (closed line) and after (dotted line) each treatment modality
100 101
Pbm (mm)
10–3
10–2
10–1
100
AS
M
 a
re
a 
(m
m2
)
Smaller 
global reduction
Larger 
local reduction
FIGURE 2 Azithromycin reduces ASM thickness in both proximal 
and distal locations compared with control (saline) mice. Area of ASM 
is normalized to Pbm. *Statistical significance at p < .05. N = 7 for 
each group, individual data points shown superimposed on box plots
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4 |  DISCUSSIONS AND 
CONCLUSIONS
This study has two key findings: first, the macrolide antibi-
otic azithromycin induces a significant reduction of ASM 
thickness in naive mice of almost 30%. Second, we consider, 
by way of a mathematical model, the potential functional con-
sequences of such a global reduction in ASM in humans, and 
find that global ASM reduction of this magnitude has similar 
functional improvement to that of BT (Donovan et al., 2018). 
F I G U R E  3  Example flow patterns in single FA case at approx. 75% of maximal ASM activation. (a) untreated; (b) global 30% reduction in 
ASM (azithromycin); (c) local 75% reduction in ASM in treated airways (BT). Flow is normalized to nominal (Donovan, 2017)
F I G U R E  4  Simulated dose-response curves comparing global reduction in ASM at various levels (10%, 20%, 30%) with BT’s 75% reduction 
in ASM in the treated central airways only. Left panel: fatal asthma (FA). Right panel: non-fatal asthma (NFA). Note that the vertical scales are 
log scales, and differ between the two panels. Error bars are standard error. *, ,  = statistical significance at p < .05 by paired t-test for untreated 
versus 10%, 20%, and 30% reduction, respectively. For clarity of comparison, resistance values are normalized to a reference value at zero ASM 
activation for each simulated patient at baseline
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F I G U R E  5  Response of the spatial 
heterogeneity index (SHI) of flow as 
contractile agonist is varied. Details as in 
Figure 4 except that a linear scale is used for 
the vertical axis
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Namely, a reduction in ventilation heterogeneity, with mini-
mal changes in resistance at baseline, but clear attenuation of 
bronchoconstriction to increasing ASM stimulation, consist-
ent with studies reporting reduced airway hyperresponsive-
ness in asthmatic patients after azithromyocin (Ekici, Ekici, 
& Erdemoglu, 2002; Piacentini et al., 2007). These findings 
demonstrate the potential of pharmacological-induced abla-
tion of the ASM layer as well advancing our understanding 
of the mechanism by which azithromycin reduces asthma 
exacerbations. Specifically, since azithromycin induced a 
notable reduction in ASM in naïve mice, as opposed to an 
allergen sensitized model, therapeutic action is independent 
of inflammation.
Azithromycin is a macrolide antibiotic that appears to 
have antibacterial, antiviral and anti-inflammatory proper-
ties. Due to these potential benefits, multiple clinical trials 
have been run regarding its efficacy in reducing asthma ex-
acerbations (Gibson et al., 2017, 2019; Johnston et al., 2016) 
and a recent meta-analysis concluded that maintenance use of 
azithromycin reduces exacerbations in patients with asthma, 
including eosinophilic, non-eosinophilic, and severe asthma 
subtypes (Hiles et  al.,  2019). The mechanism of action by 
which it does so, however, has been unclear. The present 
results suggest that reduction in ASM thickness is a plausi-
ble mechanism of action for azithromycin's role in reducing 
exacerbations in asthma, and moreover offers a possible ex-
planation for the lack of consistently demonstrable improve-
ment in conventional measures of lung function such as FEV1 
(Reiter et al., 2013), discussed below.
In terms of a direct effect on the structure of the ASM 
layer, azithromycin exhibits anti-proliferative (Stamatiou 
et al., 2009) and autophagic properties (Stamatiou, Boukas, 
Paraskeva, Molyvdas, & Hatziefthimiou,  2010), the latter 
of which may lead to apoptosis. Ongoing proliferation of 
ASM cells occurs even in non-asthmatic subjects (James 
et  al.,  2018; Stamatiou et  al.,  2010) such that any attenua-
tion in cell proliferation (or increased apoptosis) should 
reduce ASM thickness. Importantly, ASM cell cultures 
describe above (Stamatiou et  al.,  2009, 2010) were main-
tained under non-inflammatory conditions, entirely consis-
tent with our present data that azithromycin decreases ASM 
thickness in naïve mice and hence via an inflammation-in-
dependent mechanism. Azithromycin's mode of action is 
therefore quite diverse and in addition to anti-proliferative 
actions on the ASM, its range of effects includes direct re-
laxation of pre-contracted ASM (Daenas, Hatziefthimiou, 
Gourgoulianis, & Molyvdas, 2006; Massey et al., 1988), re-
duced inflammation and goblet cell hyperplasia (Beigelman 
et al., 2009; Kang et al., 2016) and maintenance of normal 
epithelial barrier function (Slater et al., 2016). None of these 
additional effects of azithromycin were considered in the 
present study which was designed to assess the functional 
consequences of reduced ASM thickness and to compare 
local changes in the large airways to more globally distrib-
uted changes in muscle mass.
If we were to assume that azithromycin's principal mech-
anism of action is reduction in ASM thickness (for analyt-
ical purposes only, acknowledging the drug's diverse mode 
of action), then the functional improvements accruing to this 
structural change may be difficult to detect at baseline, but 
instead only manifest in situations in which a higher level 
of ASM activation is present (see Figures 4 and 5, with lit-
tle-to-no change at baseline, but progressively greater im-
provement with increasing dose). For safety reasons, these 
situations are not often apparent in the clinical laboratory, 
and hence changes of this sort are relatively difficult to de-
tect using conventional measures of lung function (FEV1 
etc.). These more severe situations do still occur outside of 
the clinical testing environment, and so would be expected 
to manifest in reported exacerbations (as observed with azi-
thromycin), ACQ/AQLQ scores, and similar measurements.
The differential response to simulated pharmacological 
treatment depending on asthma severity is interesting. In FA, 
a 20% global reduction in ASM is approximately equivalent 
to the 75% ASM reduction in the BT-treated central airways. 
Changes are most apparent at the top of the dose response 
curve, but there is also a possible shift in sensitivity. In NFA, 
on the other hand, a 30% global reduction is almost exactly 
equivalent to BT, with no sensitivity shift. This difference 
between NFA and FA responses reflects the structural differ-
ences between the two groups, with the latter exhibiting not 
just greater ASM on average, but also increased heterogeneity 
(Donovan et al., 2018). The implication is that a pharmaco-
logical approach, with uniform reduction, could be relatively 
favored in more severe disease, while a local approach such 
as BT might be favored in relatively less severe disease. All 
factors being equal, treating physicians may be more in-
clined to prescribe oral administration of a pharmaceutical 
which would avoid sedation or general anesthesia and acute 
injury effects associated with BT (Castro et  al.,  2010; Cox 
et al., 2007; Pavord et al., 2007).
Much of the motivation for the present study was gen-
erated due to recent findings that gallopamil, in the context 
of a clinical trial, reduces ASM in severe asthma (Girodet 
et al., 2015). This provided a proof-of-concept that pharma-
cological agents could be used to target airway remodeling, 
in a relatively non-invasive manner compared with BT. The 
gallopamil study has, however, not been without controversy 
due to the manner in which ASM thickness was assessed 
(Sumino, Sheshadri, & Castro, 2015) and we note that gal-
lopamil may directly attenuate ASM contraction (Daenas 
et  al.,  2006; Massey et  al.,  1988). Nonetheless, the present 
finding that azithromycin has a similar effect, in mice, to that 
claimed for gallopamil in humans, strengthens the rationale 
for pharmacological agents as a means of effecting global re-
duction of ASM. The subsequent modelling is not specific to 
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azithromycin or gallopamil, but rather to a generic reduction 
in ASM of the specified level by any (likely pharmacologi-
cal) means.
Similarly, the assumed level of 75% reduction in ASM 
in the BT treated airways, though well within the range of 
reported reductions in biopsy studies, has been questioned 
(Brook, Chernyavsky, Russell, Saunders, & Brightling, 2019). 
In a subsequent publication, different levels of BT-induced 
reduction in ASM thickness were considered, and the results 
were similar with a lower assumed level of ASM reduction 
(Donovan, Elliot, Green, et al., 2019). If BT’s effective ASM 
reduction does turn out to be lower than that assumed in the 
present model, pharmacological therapies would appear rela-
tively more effective.
We have assumed that a pharmacological reduction 
in ASM, via azithromycin, gallopamil, or other possible 
agent, is likely to be a global response across all airways. 
Pharmacological reduction in ASM thickness contrasts the 
highly local nature of BT treatment, despite some evidence 
of relatively limited propagation beyond the treatment site 
(Goorsenberg et al., 2018). A relatively global reduction in 
ASM thickness in response to a pharmacological agonist 
(compared with BT) is intuitive, and supported by the finding 
that ASM at both anatomical locations was similarly reduced 
in mice. Nonetheless, due to anatomical differences in drug 
absorption or metabolism it is possible that the response to 
azithromycin is not truly global, or uniformly proportional in 
all airways. Full characterization of the within (or between) 
patient variability requires much more data than is currently 
available.
Establishing therapies that act through non-inflammatory 
pathways (beyond BT) is significant if remodeling in asthma 
also occurs independent of inflammation. Functional ab-
normalities at birth in infants who go on to develop asthma 
supports a developmental origin of remodeling (Owens, 
Laing, Zhang, & Le Souëf, 2017) and there seems to be little 
evidence in children that increased ASM thickening is pre-
ceded by inflammation (Castro-Rodriguez et al., 2018). Use 
of naïve mice ensured that any reduction in ASM thickness 
was not achieved by modulation of inflammatory processes. 
It is reasonable to query whether azithromycin would have 
been effective in an asthmatic model of asthma. Long-term 
azithromycin has been shown to reduce ASM in peripheral 
airways from mice exposed to ovalbumin and lipopolysac-
charide (Kang et al., 2016).
More broadly our findings strongly support a connec-
tion between ASM-induced airway narrowing and airway 
reactivity, going back to the seminal works of Lambert and 
Wilson (e.g., (Lambert & Wilson,  1973)). Importantly, we 
distinguish here the importance of localization and hetero-
geneity within the airway tree. While heterogeneity of ASM 
and other airway properties has been understood to be detri-
mental to function (Lutchen & Gillis, 1997; Pascoe, Seow, 
Hackett, Pare, & Donovan,  2017), similarly improvements, 
such as reduction in ASM, can also be localized; in this par-
ticular case, we consider the differences between the highly 
localized improvements of BT, confined to (or near) the treat-
ment sites, as opposed to the globally distributed effects of a 
pharmacological intervention.
In summary, azithromycin significantly reduces ASM 
thickness in naïve mice by almost 30%, and this may help to 
elucidate the underlying mechanism of azithromycin in re-
ducing asthma exacerbations. Furthermore, if such a global 
reduction in ASM can be achieved in asthma, this would 
reduce ventilation heterogeneity and improve function in a 
manner similar to that predicted to occur through BT.
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